Pharmaron (300759.SZ) has unveiled its preliminary financial results for the first half of 2025, signaling a significant downturn in profitability. The company anticipates net profit attributable to shareholders will range between 679 million yuan and 713 million yuan, reflecting a sharp year-on-year contraction of 36% to 39%. This downward trajectory contrasts with a robust performance in non-recurring items-adjusted earnings, which are projected to climb 34% to 39% year-on-year, landing between 624 million yuan and 647 million yuan. The divergent trends highlight operational headwinds impacting core profitability despite resilience in adjusted performance metrics.